Bone-targeting radiopharmaceuticals including radium-223

Cancer Journal (United States)

Volumn 19, Issue 1, 2013, Pages 71-78

  Brady, Darren ^a   Parker, Chris C ^b   O'Sullivan, Joe M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

bone metastases; Bone seeking radionuclides; castration resistant prostate cancer; radium 223

Indexed keywords

CISPLATIN; DOXORUBICIN; ESTRAMUSTINE; KETOCONAZOLE; PACLITAXEL; PHOSPHORUS 32; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RHENIUM 186; RHENIUM 188; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG; VINBLASTINE; ZOLEDRONIC ACID;

BETA RADIATION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DOSIMETRY; DRUG HALF LIFE; GAMMA RADIATION; HUMAN; LINEAR ENERGY TRANSFER; LOW DRUG DOSE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOBIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOPHARMACEUTICALS; RADIUM;

EID: 84873864130     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318282479b     Document Type: Review

References (63)

1. Liepe K, Geidel H, Bergmann R, et al. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer. Nucl Med Commun. 2009;30(9):693-699. Available at: http://www.ncbi. nlm.nih.gov/pubmed/19528873. Accessed October 2, 2012.
2. Samaratunga RC, Thomas SR, Hinnefeld JD, et al. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP. J Nucl Med. 1995;36:336-350. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 7830140.
3. Silberstein EB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med. 2005;35:152-158. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15765378. Accessed July 18, 2012.
4. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribu-tion and dosimetry estimation. J Nucl Med. 1993;34:1031-1036. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7686217.
5. Singh A, Holmes R, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989;30: 1814-1818. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2478681.
6. Dafermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med. 2001;28:788-798.
7. 153Sm-EDTMP. EurJNucl Med Mol Imaging.2009;36:122-129. Available at: http://www. ncbi.nlm.nih.gov/pubmed/18751975. Accessed October 23, 2012.
8. 186Re-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging. 2003;30:1114-1124. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 12761596. Accessed October 2, 2012.
9. Farhanghi M, Holmes RA, Volkert WA, et al. Toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;1451-1458.
10. 90Y bremsstrahlung whole-body imaging. Phys Med Biol. 2009;54:5873-5883. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19759410. Accessed August 2, 2012.
11. 90Y Bremsstrahlung imaging for absorbed-dose as sessment in high-dose radioimmunotherapy. J Nucl Med. 2010;51:1974-1978. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21078799. Accessed July 12, 2012.
12. Brahme A. Accurate description of the cell survival and biological effect at low and high doses and LET's. Journal of Radiation Research. 2011;52:389-407. Available at: http://joi.jlc.jst.go.jp/JST.JSTAGE/jrr/10129? from=CrossRef. Accessed August 31, 2012.
13. Wenzl T, Wilkens JJ. Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications. Radiat Oncol (London, England). 2011;6:171. Available at: http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=3283483&tool= pmcentrez&rendertype=abstract. Accessed September 30, 2012.
14. Barendsen GW, Koot CJ, Van Kersen GR, et al. The effect of oxygen on impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET. Int J Radiat Biol Relat Stud Phys Chem Med. 1966;10:317-327. Available at: http://www.ncbi.nlm.nih. gov/pubmed/5297012. Accessed October 2, 2012.
15. Sgouros G, Roeske JC, McDevitt MR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311-328. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20080889.
16. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol. 2012;30(supp 5). Abstract 8.
17. 89Sr in palliation in skeletal metasta-ses. J Nucl Med. 1999;40:256-261. Available at: http://www.ncbi.nlm. nih.gov/pubmed/10025832.
18. Dickie GJ, Macfarlane D. Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol. 1999;43:476-479. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10901963.
19. Liepe K, Franke WG, Kropp J, et al. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases. Nuklearmedizin. 2000;39:146-151.
20. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer. A systemic review. Lancet Oncol. 2005;6: 392-400.
21. Olea E, Quintana JC, Nagel J, et al. Efficacy and toxicity of samarium-153-EDTMP locally produced in the treatment of painful skeletal metastases results of an IAEA international multicenter study [abstract]. J Nucl Med. 2000;41(suppl):123-130.
22. Zafeirakis A, Papatheodorou G, Arhontakis A, et al. Predictive implications of bone turnover markers after palliative treatment with (186) Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases. Eur J Nucl Med Mol Imaging. 2010;37:103-113. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19662405. Accessed October 23, 2012.
23. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMPin bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34:1839-1844.
24. Palmedo H, Guhlke S, Bender H. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med. 2000;27. Available at: http://www.springerlink.com/ index/YH7Q55U0NP608VYG.pdf. Accessed October 23, 2012.
25. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer (Oxford, England: 1990). 2012;48:678-686. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22341993. Accessed July 20, 2012.
26. O'Sullivan JM, McCready VR, Flux G, et al. High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metas-tatic to bone. Br J Cancer. 2002;86:1715-1720. Available at: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=2375418&tool= pmcentrez&rendertype=abstract. Accessed July 19, 2012.
27. 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging. 2006;33:1055-1061. Available at: http://www.springerlink.com/content/d4p409348832v430/. Accessed October 8, 2012.
28. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8478230. Accessed October 4, 2012.
29. Foss SD, Paus E, Lochoff M, et al. Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. Br J Cancer. 1992;871:177-180.
30. Buchali K, Correns HJ, Schuerer M, et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med. 1988;14:349-351. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 2460352. Accessed October 9, 2012.
31. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydro- xyethylidenediphosphonate. J Clin Oncol. 2003;21:2869-2875. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12885803. Accessed July 9, 2012.
32. Resche I, Chatal D, Pecking A, et al. A dose-controlled study of 15'Sm-ethylenediamine tetramethylene phosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583-1591.
33. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336-341. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 11210994.
34. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79-86. Available at: http://www.ncbi. nlm.nih.gov/pubmed/11801708.
35. Sciuto R, Maini CL, Tofani A, et al. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun. 1996;17:799-804. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/8895908. Accessed October 23, 2012.
36. Akerley W, Butera J, Wehbe T, et al. A multi-institutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine involving bone. Cancer. 2002;94:1654-1660.
37. Lam MGEH, Dahmane A, Stevens WHM, et al. (188) Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. Eur J Nucl Med Mol Imaging. 2009;36:1425-1433. Available at: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=2724641&tool= pmcentrez&rendertype=abstract. Accessed July 30, 2012.
38. 186Re-HEDP in castration-resistant prostate cancer (CRPC) meta-static to bone (the TAXIUM trial). Eur J Nucl Med Mol Imaging. 2011; 38:1990-1998. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21792569. Accessed October 23, 2012.
39. Tu SM, Mathew P, Wong FC, et al. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27:3319-3324. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19414670. Accessed July 30, 2012.
40. 153Sm-lexidronam in patients with castration-resistant metast-atic prostate cancer. Urol Oncol. 2011;29:670-675. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19962920. Accessed July 30, 2012.
41. 153Sm- lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience. Cancer Biother Radiopharm. 2008;23:609-618. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18999933. Accessed October 23, 2012.
42. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27:2429-2435. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19364971. Accessed July 30, 2012.
43. Morris MJ, Hammers HJ, Sweeney C, et al. A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases. J Clin Oncol. 2012;30(15 suppl):TPS4694.
44. 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging. 2008;35:756-765. Available at: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=2668561&tool= pmcentrez&rendertype= abstract. Accessed July 9, 2012.
45. Marcus CS, Saeed S, Mlikotic A, et al. Lack of effect of a bisphospho-nate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clinical nuclear medicine. 2002;27:427-430. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12045435. Accessed October 23, 2012.
46. Storto G, Klain M, Paone G, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone. 2006; 39:35-41. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16434248. Accessed May 31, 2012.
47. Smeland S, Erikstein B, Aas M, et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys. 2003;56:1397-1404. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0360301603002748. Accessed May 30, 2012.
48. Valicenti RK, Trabulsi E, Intenzo C, et al. A phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study. Int J Radiat Oncol Biol Phys. 2011;79:732-737. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 20399029. Accessed July 30, 2012.
49. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-106. Available at: http://www.ncbi.nlm.nih. gov/pubmed/12126818.
50. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821-827. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15315996.
51. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378:2104-2111. Available at: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=3243932&tool= pmcentrez&rendertype= abstract. Accessed October 14, 2012.
52. Cook GJR, Venkitaraman R, Sohaib AS, et al. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging. 2011;38:7-13. Available at: http://www. ncbi.nlm.nih.gov/ pubmed/20697891. Accessed October 17, 2012.
53. 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun. 2007;28:245-250. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17325585. Accessed October 4, 2012.
54. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer (Oxford, England: 1990). 1991;27:954-958. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1716935. Accessed October 4, 2012.
55. Maxon HR, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med. 1991;32:1877-1881. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1717669. Accessed October 4, 2012.
56. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-945. Available at: http://www.ncbi. nlm.nih.gov/pubmed/ 15134985. Accessed June 20, 2012.
57. Sciuto R, Festa A, Pasqualoni R, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat. 2001;66:101-109.
58. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9552068. Accessed October 9, 2012.
59. Oosterhof GON, Roberts JT, de Reijke TM, et al. Strontium89 chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer Genitourinary Group. Eur Urol. 2003;44:519-526. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0302283803003646. Accessed October 16, 2012.
60. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008; 299:1914-1921.
61. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952.
62. Non-small Cell Lung Cancer Collaberative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. N Engl J Med.1995;311:899-909.
63. Of O. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol.2008;26:5802-5812.